Janssen Search
Search results
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma
Sep 20, 2024 Belgium Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed 60 percent reduction in risk of disease progression or death with ...
Innovations in the Interception of Lung Cancer: How a Smartphone App May Aid Smoking Cessation in China
Innovations in the Interception of Lung Cancer: How a Smartphone App May Aid Smoking Cessation in China Many risk factors of lung cancer are known, and its pre-malignant state continues to emerge through insights in genetic markers, disease heterogeneity ...
Sustainable Practices- Green Chemistry
Green Chemistry: Innovation in Chemical Development The emerging attention on the responsible use of pharmaceutical chemicals is the focus of our new Janssen.com series on green chemistry. Below, you can learn about green chemistry and Janssen’s longtime ...
Stopping Type 1 Diabetes Before It Starts
Stopping Type 1 Diabetes Before It Starts Each year, World Diabetes Day is celebrated on November 14, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922. For nearly a century, insulin has been helping people ...
World AIDS Day 2021: How Far We’ve Come, and Yet to Go
World AIDS Day 2021: How Far We’ve Come, and Yet to Go In the more than 40 years since the global HIV epidemic began, the world has made significant progress against the virus. Major strides have been taken in developing treatment and prevention options ...
Story – Going Green in Switzerland
Going Green in Switzerland One J&J Zug, a Johnson & Johnson Family of Companies regional headquarters in Zug, Switzerland, is a state-of-the-art facility designed to meet 21 st century needs. The local team focuses on how its facilities improve ...
Mental Health Partnerships in Asia Pacific
Fostering Mental Health Partnerships in Asia Pacific In Asia Pacific, as in many regions around the world, there is a stigma surrounding mental illness, resulting from a lack of awareness and education about mental health disorders. Despite their high ...
See the Change, Be the Change
See the Change; Be the Change – Global Regulatory Affairs Colleagues Are Shaping the Future As Nelson Mandela said, “Education is the most powerful weapon which you can use to change the world.” Each September, I think about the millions of eager students ...
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
Apr 22, 2024 Belgium Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse [1] Approval is based on results from the PHASE 3 CARTITUDE-4 study, in ...
European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma
Aug 23, 2024 Belgium First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR 3 alterations Approval based on THOR results, showing 36 percent ...